Hormonal
Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, achieves up to 24.2% weight loss over 48 weeks.
Retatrutide is an investigational once-weekly injection that targets GLP-1, GIP, and glucagon receptors, achieving up to 24.2% weight loss over 48 weeks in clinical trials. It is not yet fully approved but shows promise for obesity and type 2 diabetes. Potential side effects include gastrointestinal issues and transient heart rate elevations.
Findings from phase 1 to phase 3 clinical trials highlight retatrutide’s significant therapeutic efficacy, with marked reductions in body weight (up to 24.2% over 48 weeks)
Why this rating
Based on phase 1-3 trials, but not yet fully approved for widespread use.
Source
Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies
Mohammad I. Ullah et al. · Medicines · 2025
DOI 10.3390/medicines12030019
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →